DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-0327
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Differentiation Therapy in Acute Myelogenous Leukemia (Non-Apl)

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Therapy-Related Myelodysplastic Syndrome-Acute Myelogenous Leukemia in Patients Treated for Acute Promyelocytic Leukemia: An Emerging Problem

Blood
BiochemistryImmunologyCell BiologyHematology
2002English

New Agents for Acute Myelogenous Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Treatment of Acute Myelogenous Leukemia in Older Adults

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

P53 in Chronic Myelogenous Leukemia in Acute Phase.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1991English

Heterogeneous Patterns of CEBP Mutation Status in the Progression of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia to Acute Myelogenous Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2005English

Acute Myelogenous Leukemia With Leptotrichia Trevisanii Bacteremia

Internal Medicine
Internal MedicineMedicine
2013English

Examination of the FLT3 and NPM1 Mutational Status in Patients With Acute Myeloid Leukemia From Southeastern Poland

Archives of Medical Science
Medicine
2016English

Specific Induction of Erythroleukemia and Myelogenous Leukemia in Sprague-Dawley Rats.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1982English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy